Ap Biosciences Inc.

Allgenesis Biotherapeutics Inc.

Ching-Hsuan Hsu

Jeng-Horng Her

Jhong-Jhe You

Po-Lin Huang

Hsin-Ta Hsieh

Hung-Tsai Kan

Ting-Yi Chang

Huang-Tsu Chen

Pei-Tzu Wu

Jiun-Shyang Leou

Kevin Zen

PO-Lin Huang

Antibodies that include an antigen binding region that binds to CD137 are provided herein. Also provided herein are bispecific antibodies that include a first antigen binding region that binds to CD137 and a second antigen binding region that binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen. Pharmaceutical compositions that include the antibodies and methods of treating cancer are provided.

Bispecific CD137-binding antibodies for T-cell activation

Provided are monospecific and bispecific proteins that bind specifically to OX40 and/or PD-L1. Exemplary proteins release the inhibition through PD-L1 and stimulate T cell through OX40. Exemplary polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, the binding sites may be linked through an immunoglobulin constant region. Anti-OX40 and anti-PD-L1 antibodies are also provided.

PD-L1 and OX40 binding proteins for cancer regulation

Provided are bispecific proteins that comprise a binding domain binding cell surface protein and a vascular endothelial growth factor (VEGF) inhibiting domain. Provided also is an antibody-drug conjugate that comprises a therapeutic agent and an antibody or an antigen-binding fragment binding PD-L1 and/or a VEGF inhibiting domain, wherein the therapeutic agent is covalently conjugated to the antibody or the antigen-binding fragment by a linker.

Bifunctional proteins combining checkpoint blockade for targeted therapy

CD137 antibodies for T-cell activation

PD-L1 and OX40 binding proteins for cancer Regulation

Fusion proteins containing a PDGF binding portion, a VEGF binding portion, and an Fc antibody region are described. Also described are nucleic acids encoding the fusion proteins, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing clinical conditions characterized by abnormal angiogenesis, such as vascular permeability, edema or inflammation.

Fusion protein comprising a ligand binding domain of VEGF and PDGF

Growing community of inventors

Taipei, Taiwan

Ching-Hsuan Hsu